Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victoria M Villaflor

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Current Treatment Options in Oncology|June 15, 2023
Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?Juan Jose Juarez-Vignon Whaley, Michelle Afkhami, Mykola Onyshchenko, et al.
International Journal of Surgical Pathology|May 13, 2017
Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to CrizotinibNicole A Cipriani, Elizabeth A Blair, Joshua Finkle, et al.
Oncotarget|November 17, 2016
Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trialsRicardo Costa, Benedito A Carneiro, Mark Agulnik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxibMary J Fidler, Athanassios Argiris, Jyoti D Patel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 3, 2009
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trialsRogerio Lilenbaum, Victoria M Villaflor, Corey Langer, et al.
Cold Spring Harbor Molecular Case Studies|April 28, 2022
Prolonged response to checkpoint inhibitor therapy in two metastatic mucoepidermoid salivary gland carcinoma cases: a research reportRebecca R Pharaon, Thomas Gernon, Sue Chang, et al.
Journal of Carcinogenesis|December 10, 2013
O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancerRifat Hasina, Mosmi Surati, Ichiro Kawada, et al.
Oncotarget|December 29, 2016
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationYoung Kwang Chae, Keerthi Ranganath, Peter S Hammerman, et al.
Head & Neck Oncology|July 28, 2011
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignanciesAaron W Pederson, Joseph K Salama, Daniel J Haraf, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2007
The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinibLela E Buckingham, John S Coon, Larry E Morrison, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Current Treatment Options in Oncology|June 15, 2023
Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?Juan Jose Juarez-Vignon Whaley, Michelle Afkhami, Mykola Onyshchenko, et al.
International Journal of Surgical Pathology|May 13, 2017
Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to CrizotinibNicole A Cipriani, Elizabeth A Blair, Joshua Finkle, et al.
Oncotarget|November 17, 2016
Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trialsRicardo Costa, Benedito A Carneiro, Mark Agulnik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxibMary J Fidler, Athanassios Argiris, Jyoti D Patel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 3, 2009
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trialsRogerio Lilenbaum, Victoria M Villaflor, Corey Langer, et al.
Cold Spring Harbor Molecular Case Studies|April 28, 2022
Prolonged response to checkpoint inhibitor therapy in two metastatic mucoepidermoid salivary gland carcinoma cases: a research reportRebecca R Pharaon, Thomas Gernon, Sue Chang, et al.
Journal of Carcinogenesis|December 10, 2013
O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancerRifat Hasina, Mosmi Surati, Ichiro Kawada, et al.
Oncotarget|December 29, 2016
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationYoung Kwang Chae, Keerthi Ranganath, Peter S Hammerman, et al.
Head & Neck Oncology|July 28, 2011
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignanciesAaron W Pederson, Joseph K Salama, Daniel J Haraf, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2007
The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinibLela E Buckingham, John S Coon, Larry E Morrison, et al.
Pageof 5